APPROVED FOR TREATMENT AFTER SURGERY FOR 1 FULL YEAR (UP TO 18 CYCLES)
PERJETA® (pertuzumab) is approved in combination with Herceptin® (trastuzumab) and chemotherapy for patients with HER2+ early breast cancer that has a high likelihood of coming back.
An easy-to-use app from Genentech for patients with HER2-positive
PERJETA Access Solutions may be able to help you get the PERJETA you need, even if you can’t pay for it.
Learn about PERJETA in other treatment settings
Find more information and resources on PERJETA.com